Wild-type (senile) amyloidosis other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 42: | Line 42: | ||
| pmid = 27143678 | | pmid = 27143678 | ||
}}</ref> | }}</ref> | ||
* | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 18:47, 19 December 2019
Wild-type (senile) amyloidosis Microchapters |
Differentiating Wild-type (senile) amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) amyloidosis other imaging findings On the Web |
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other imaging findings |
FDA on Wild-type (senile) amyloidosis other imaging findings |
CDC on Wild-type (senile) amyloidosis other imaging findings |
Wild-type (senile) amyloidosis other imaging findings in the news |
Blogs on Wild-type (senile) amyloidosis other imaging findings |
Risk calculators and risk factors for Wild-type (senile) amyloidosis other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Other Imaging Findings
Nuclear Imaging
- Bone-avid tracers, such as 99mTc-DPD (technetium-3,3-diphosphono-1,2-propanodicar-boxylic acid), 99mTc-PYP (technetium-pyrophosphate), and 99mTc-HMDP [technetium-hydroxymethylene diphosphonate (Tc-HMDP)] have been implicated to have high sensitivity and specificity for diagnosing cardiac amyloidosis and differentiating it from other cardiomyopathies with HFpEF.[1][2]
- Combination of grade 2 or 3 cardiac uptake on a bone-avid tracer scan in the setting of absent monoclonal protein by serum immunofixation electrophoresis (IFE), urine IFE, and serum free light chain assay is diagnostic of wild-type (senile) cardiac amyloidosis.[3]
References
- ↑ Enrica Perugini, Pier Luigi Guidalotti, Fabrizio Salvi, Robin M. T. Cooke, Cinzia Pettinato, Letizia Riva, Ornella Leone, Mohsen Farsad, Paolo Ciliberti, Letizia Bacchi-Reggiani, Francesco Fallani, Angelo Branzi & Claudio Rapezzi (2005). "Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy". Journal of the American College of Cardiology. 46 (6): 1076–1084. doi:10.1016/j.jacc.2005.05.073. PMID 16168294. Unknown parameter
|month=
ignored (help) - ↑ Sabahat Bokhari, Rachelle Morgenstern, Richard Weinberg, Mona Kinkhabwala, Demetrios Panagiotou, Adam Castano, Albert DeLuca, Andrew Kontak, Zhezhen Jin & Mathew S. Maurer (2018). "Standardization of (99m)Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis". Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 25 (1): 181–190. doi:10.1007/s12350-016-0610-4. PMID 27580616. Unknown parameter
|month=
ignored (help) - ↑ Julian D. Gillmore, Mathew S. Maurer, Rodney H. Falk, Giampaolo Merlini, Thibaud Damy, Angela Dispenzieri, Ashutosh D. Wechalekar, John L. Berk, Candida C. Quarta, Martha Grogan, Helen J. Lachmann, Sabahat Bokhari, Adam Castano, Sharmila Dorbala, Geoff B. Johnson, Andor W. J. M. Glaudemans, Tamer Rezk, Marianna Fontana, Giovanni Palladini, Paolo Milani, Pierluigi L. Guidalotti, Katarina Flatman, Thirusha Lane, Frederick W. Vonberg, Carol J. Whelan, James C. Moon, Frederick L. Ruberg, Edward J. Miller, David F. Hutt, Bouke P. Hazenberg, Claudio Rapezzi & Philip N. Hawkins (2016). "Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis". Circulation. 133 (24): 2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612. PMID 27143678. Unknown parameter
|month=
ignored (help)